NASDAQ:MGEN - Miragen Therapeutics Stock Price, Forecast & News

Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGEN shares have decreased by 23.8% and is now trading at $0.4664. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Miragen Therapeutics.

Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Miragen Therapeutics.

Miragen Therapeutics Inc (NASDAQ:MGEN) issued its earnings results on Wednesday, March, 11th. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.06. The medical research company had revenue of $0.88 million for the quarter, compared to analysts' expectations of $0.97 million. Miragen Therapeutics had a negative return on equity of 147.81% and a negative net margin of 938.65%. View Miragen Therapeutics' earnings history.

3 equities research analysts have issued 12-month price targets for Miragen Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they expect Miragen Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 1,079.2% from the stock's current price. View analysts' price targets for Miragen Therapeutics.

Media headlines about MGEN stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Miragen Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View the latest news aboutMiragen Therapeutics.

Miragen Therapeutics saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 292,600 shares, a drop of 35.2% from the February 27th total of 451,200 shares. Based on an average trading volume of 1,550,200 shares, the short-interest ratio is currently 0.2 days. Currently, 1.0% of the company's stock are short sold. View Miragen Therapeutics' Current Options Chain.

Some companies that are related to Miragen Therapeutics include Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Psychemedics (PMD), Biocept (BIOC), OpGen (OPGN), Avant Diagnostics (AVDX), CBA Florida (CBAI), PotNetwork (POTN), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Bellicum Pharmaceuticals (BLCM), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Genocea Biosciences (GNCA), SCYNEXIS (SCYX) and Trevena (TRVN).

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

Miragen Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.46%), Wedbush Securities Inc. (0.28%), Game Plan Financial Advisors LLC (0.18%), Goldman Sachs Group Inc. (0.17%) and Virtu Financial LLC (0.16%). View institutional ownership trends for Miragen Therapeutics.

MGEN stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View insider buying and selling activity for Miragen Therapeutics.

MGEN stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wedbush Securities Inc., Game Plan Financial Advisors LLC, and Virtu Financial LLC. View insider buying and selling activity for Miragen Therapeutics.

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGEN stock can currently be purchased for approximately $0.47.

Miragen Therapeutics has a market capitalization of $24.75 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe. View additional information about Miragen Therapeutics.

The official website for Miragen Therapeutics is http://www.miragen.com/.

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]